Literature DB >> 33371501

QSAR Model for Predicting the Cannabinoid Receptor 1 Binding Affinity and Dependence Potential of Synthetic Cannabinoids.

Wonyoung Lee1, So-Jung Park1, Ji-Young Hwang1, Kwang-Hyun Hur1, Yong Sup Lee2, Jongmin Kim3, Xiaodi Zhao1, Aekyung Park4, Kyung Hoon Min3, Choon-Gon Jang1, Hyun-Ju Park1.   

Abstract

In recent years, there have been frequent reports on the adverse effects of synthetic cannabinoid (SC) abuse. SCs cause psychoactive effects, similar to those caused by marijuana, by binding and activating cannabinoid receptor 1 (CB1R) in the central nervous system. The aim of this study was to establish a reliable quantitative structure-activity relationship (QSAR) model to correlate the structures and physicochemical properties of various SCs with their CB1R-binding affinities. We prepared tetrahydrocannabinol (THC) and 14 SCs and their derivatives (naphthoylindoles, naphthoylnaphthalenes, benzoylindoles, and cyclohexylphenols) and determined their binding affinity to CB1R, which is known as a dependence-related target. We calculated the molecular descriptors for dataset compounds using an R/CDK (R package integrated with CDK, version 3.5.0) toolkit to build QSAR regression models. These models were established, and statistical evaluations were performed using the mlr and plsr packages in R software. The most reliable QSAR model was obtained from the partial least squares regression method via Y-randomization test and external validation. This model can be applied in vivo to predict the addictive properties of illicit new SCs. Using a limited number of dataset compounds and our own experimental activity data, we built a QSAR model for SCs with good predictability. This QSAR modeling approach provides a novel strategy for establishing an efficient tool to predict the abuse potential of various SCs and to control their illicit use.

Entities:  

Keywords:  cannabinoid receptor 1; dependence and abuse potential; multiple linear regression; partial least squares regression; quantitative structure-activity relationship; synthetic cannabinoids

Mesh:

Substances:

Year:  2020        PMID: 33371501      PMCID: PMC7767513          DOI: 10.3390/molecules25246057

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  26 in total

1.  Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Authors:  Sherrica Tai; William E Fantegrossi
Journal:  Curr Addict Rep       Date:  2014-06-01

2.  A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models.

Authors:  Shuxing Zhang; Alexander Golbraikh; Scott Oloff; Harold Kohn; Alexander Tropsha
Journal:  J Chem Inf Model       Date:  2006 Sep-Oct       Impact factor: 4.956

3.  Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.

Authors:  John W Huffman; Alicia L S Thompson; Jenny L Wiley; Billy R Martin
Journal:  Bioorg Med Chem       Date:  2007-09-22       Impact factor: 3.641

4.  Synthesis of oxidative metabolites of CRA13 and their analogs: Identification of CRA13 active metabolites and analogs thereof with selective CB2R affinity.

Authors:  Ahmed H E Hassan; Min Chang Cho; Hye In Kim; Ji Seul Yang; Kyung Tae Park; Ji Young Hwang; Choon-Gon Jang; Ki Duk Park; Yong Sup Lee
Journal:  Bioorg Med Chem       Date:  2018-09-06       Impact factor: 3.641

5.  Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.

Authors:  Maren Hermanns-Clausen; Stefan Kneisel; Bela Szabo; Volker Auwärter
Journal:  Addiction       Date:  2012-11-01       Impact factor: 6.526

6.  Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding.

Authors:  M M Aung; G Griffin; J W Huffman; M Wu; C Keel; B Yang; V M Showalter; M E Abood; B R Martin
Journal:  Drug Alcohol Depend       Date:  2000-08-01       Impact factor: 4.492

7.  JWH-018 in rhesus monkeys: differential antagonism of discriminative stimulus, rate-decreasing, and hypothermic effects.

Authors:  Jesse S Rodriguez; Lance R McMahon
Journal:  Eur J Pharmacol       Date:  2014-06-24       Impact factor: 4.432

8.  Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.

Authors:  Edward K Dziadulewicz; Stuart J Bevan; Christopher T Brain; Paul R Coote; Andrew J Culshaw; Andrew J Davis; Lee J Edwards; Adrian J Fisher; Alyson J Fox; Clive Gentry; Alex Groarke; Terance W Hart; Werner Huber; Iain F James; Adam Kesingland; Luigi La Vecchia; Yvonne Loong; Isabelle Lyothier; Kara McNair; Cathal O'Farrell; Marcus Peacock; Robert Portmann; Ulrich Schopfer; Mohammed Yaqoob; Jiri Zadrobilek
Journal:  J Med Chem       Date:  2007-07-14       Impact factor: 7.446

9.  Dependence Potential of the Synthetic Cannabinoids JWH-073, JWH-081, and JWH-210: In Vivo and In Vitro Approaches.

Authors:  Hye Jin Cha; Kwang-Wook Lee; Min-Ji Song; Yang-Jin Hyeon; Ji-Young Hwang; Choon-Gon Jang; Joon-Ik Ahn; Seol-Hee Jeon; Hyun-Uk Kim; Young-Hoon Kim; Won-Keun Seong; Hoil Kang; Han Sang Yoo; Ho-Sang Jeong
Journal:  Biomol Ther (Seoul)       Date:  2014-07       Impact factor: 4.634

Review 10.  An Update of Current Cannabis-Based Pharmaceuticals in Pain Medicine.

Authors:  Ivan Urits; Matthew Borchart; Morgan Hasegawa; Justin Kochanski; Vwaire Orhurhu; Omar Viswanath
Journal:  Pain Ther       Date:  2019-02-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.